Pharmacokinetics and tolerance study of intravitreal injection of dexamethasone-loaded nanoparticles in rabbits.
The aim of the study was to investigate the tolerance and pharmacokinetics of dexamethasone (DEX)-loaded poly(lactic acid-co-glycolic acid) nanoparticles (DEX-NPs) in rabbits after intravitreal injection. The DEX-NPs were prepared and characterized in terms of morphology, particle size and size distribution, encapsulation efficiency, and in vitro release. Ophthalmic investigations were performed, including fundus observation and photography, intraocular pressure measurement, and B-scan ocular ultrasonography. There were no abnormalities up to 50 days after administration of DEX-NPs in rabbits. The DEX concentrations in plasma and the ocular tissues such as the cornea, aqueous humor, lens, iris, vitreous humor, and chorioretina were determined by high-pressure liquid chromatography. The DEX-NPs maintained a sustained release of DEX for about 50 days in vitreous and provided relatively constant DEX levels for more than 30 days with a mean concentration of 3.85 mg/L(-1). Based on the areas under the curve, the bioavailability of DEX in the experimental group was significantly higher than that in the control group injected with regular DEX. These results suggest that intravitreal injection of DEX-NPs lead to a sustained release of DEX with a high bioavailability, providing a basis for a novel approach to the treatment of posterior segment diseases.
Zhang
Linhua
L
Institute of Biomedical Engineering, Peking Union Medical College and Chinese Academy of Medical Sciences, Tianjin 300192, China.
Li
Yue
Y
Zhang
Chao
C
Wang
Yusheng
Y
Song
Cunxian
C
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D003907:Dexamethasone / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics*; D004337:Drug Carriers / Q000009:adverse effects / Q000737:chemistry*; D005260:Female; D007267:Injections; D008297:Male; D053758:Nanoparticles / Q000009:adverse effects / Q000737:chemistry*; D009798:Ocular Hypertension / Q000139:chemically induced / Q000175:diagnosis; D011817:Rabbits; D014822:Vitreous Body / Q000187:drug effects* / Q000378:metabolism*
D000893:Anti-Inflammatory Agents; D004337:Drug Carriers; D003907:Dexamethasone